Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Study ID: NCT03537482
Start Date: 2018-08-07
End Date: 2025-02-15
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

90

Intervention / Treatment

APG-2575

Sponsor

Ascentage Pharma Group Inc.

Source: clinicaltrials.gov

Share:
Add to list

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Study ID: NCT04164082
Start Date: 2020-03-18
End Date: 2026-03-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

161

Intervention / Treatment

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Cystoscopy

Gemcitabine Hydrochloride

Magnetic Resonance Imaging

Pembrolizumab

Transurethral Resection of Bladder Tumor

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Study ID: NCT04064827
Start Date: 2020-09-16
End Date: 2026-10
Study Type

Interventional

Study Phase

Phase3

No. of Participants

16

Intervention / Treatment

Paricalcitol

Sponsor

AbbVie

Source: clinicaltrials.gov

Share:
Add to list

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Study ID: NCT03351348
Start Date: 2017-11-16
End Date: 2026-11
Study Type

Interventional

Study Phase

Phase3

No. of Participants

144

Intervention / Treatment

Bupivacaine

patient-reported pain scores

saline

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Study ID: NCT03587844
Start Date: 2018-07-03
End Date: 2026-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

58

Intervention / Treatment

Bentuximab Vidotin

Bentuximab Vidotin

Bentuximab Vidotin

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Study ID: NCT04701476
Start Date: 2021-05-20
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

110

Intervention / Treatment

TATE and pembrolizumab

Tas-102 pill

Regorafenib Pill

Sponsor

Teclison Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Study ID: NCT04725994
Start Date: 2021-06-28
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

IDX-1197+XELOX

IDX-1197+Irinotecan

Sponsor

Idience Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Study ID: NCT05557591
Start Date: 2023-04-21
End Date: 2027-06-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

BNT116

Cemiplimab

Sponsor

Regeneron Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Study ID: NCT05483491
Start Date: 2022-09-26
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

30

Intervention / Treatment

KK-LC-1 TCR-T cells

Aldesleukin

Sponsor

Christian Hinrichs

Source: clinicaltrials.gov

Share:
Add to list

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Study ID: NCT05036291
Start Date: 2021-10-01
End Date: 2026-09-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

120

Intervention / Treatment

NB004 tablets

Sponsor

Ningbo Newbay Technology Development Co., Ltd

Source: clinicaltrials.gov

Share:
Add to list